Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2020 | The need for biomarkers to begin clinical trials for ataxia treatment

Henry Paulson • 9 Sep 2020
MDS 2020
Huntington’s Disease Movement Disorders

Henry Paulson, MD, PhD, University of Michigan, Ann Arbor, MI, discusses the need for biomarkers to measure the severity of ataxia. The current clinical scales are inherently low resolution and are not sophisticated enough to form clinical trials for potential treatment. With biomarkers, better imaging and better biomolecule detection, clinical trials can commence to find a treatment for these fatal diseases. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).

More from Henry Paulson

2:29
The role of polyglutamine, epigenetics and RNA in Huntington’s disease
Henry Paulson • 9 Sep 2020
2:31
Introduction to repeat expansion diseases
Henry Paulson • 9 Sep 2020

Related Videos

1:19
The potential of cell and gene therapy in treating Parkinson’s disease
Fabrizio Stocchi • 7 Mar 2024
4:11
Updates on current Parkinson’s disease clinical trials
Fabrizio Stocchi • 7 Mar 2024
3:42
NfL shows strong prognostic value in pre-manifest Huntington's disease
Natalia E. Owen • 8 Mar 2024
5:26
Pridopidine shows benefit for patients with early HD not on antidopaminergic therapies
Michael Hayden • 16 Apr 2024
The content of VJNeurology is intended for healthcare professionals